RECRUITING

Study to Evaluate the Maximal Use of Ruxolitinib Cream in Adult and Adolescent Participants With Hidradenitis Suppurativa

Description

The purpose of this study is to evaluate the maximal use of ruxolitinib cream in adult and adolescent participants with hidradenitis suppurativa.

Conditions

Hidradenitis Suppurativa
Talk to us

Related Conditions:

Hidradenitis Suppurativa

Study Overview

On this page

Study Details

Study overview

The purpose of this study is to evaluate the maximal use of ruxolitinib cream in adult and adolescent participants with hidradenitis suppurativa.

A Maximal Use Trial of Ruxolitinib Cream in Adult and Adolescent Participants With Hidradenitis Suppurativa

Study to Evaluate the Maximal Use of Ruxolitinib Cream in Adult and Adolescent Participants With Hidradenitis Suppurativa

Condition
Hidradenitis Suppurativa
Intervention / Treatment

-

Contacts and Locations

Phoenix

Saguaro Dermatology, Phoenix, Arizona, United States, 85008

Fountain Valley

First Oc Dermatology, Fountain Valley, California, United States, 92708

Newbury Park

Clinical Trials Research Institute, Newbury Park, California, United States, 91320

Northridge

Amicis Research Center, Northridge, California, United States, 91324

Sanford

International Clinical Research Us Llc Sanford, Sanford, Florida, United States, 32771

Sweetwater

Lenus Research Medical Group, Llc, Sweetwater, Florida, United States, 33172

Tampa

Trueblue Clinical Research, Tampa, Florida, United States, 33609

Atlanta

Emory University Dermatology Research Department, Atlanta, Georgia, United States, 30322

Columbus

Lane Dermatology and Dermatologic Surgery, Columbus, Georgia, United States, 31904

Bowling Green

Equity Medical, Llc, Bowling Green, Kentucky, United States, 42104

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Diagnosis of HS for at least 6 months before screening visit.
  • * Diagnosis of HS (Hurley Stage I, II, III) with a total abscess and inflammatory nodule count of at least 4 and affecting at least 3 distinct anatomical areas at screening and Day 1 visits.
  • * Total estimated treatment BSA \> 20% at screening and baseline.
  • * Agreement to not use topical or systemic antibiotics for treatment of HS during the Maximal Use Treatment Period.
  • * Willingness to avoid pregnancy or fathering children based on the criteria defined in the protocol.
  • * Further inclusion criteria apply.
  • * Current or history of skin condition(s) other than HS that might confound the evaluation of HS; clinically uncontrolled cardiovascular disease; thrombosis; certain cancers; certain infections; severe anemia, thrombocytopenia, or neutropenia; other medical conditions at the discretion of the investigator.
  • * Laboratory values outside of the protocol-defined ranges.
  • * Further exclusion criteria apply.

Ages Eligible for Study

12 Years to 75 Years

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Incyte Corporation,

Incyte Medical Monitor, STUDY_DIRECTOR, Incyte Corporation

Study Record Dates

2026-12-09